Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:24:33.501Z.
Calculation as of: 2026-10-06T19:24:33.501Z.
Quote observation: 2026-10-06T19:19:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc3fa1fa429e6ac4f0d7012b2af5cf8e78abb5153a19c38995711b2f102458f4
PE RATIO
N/A
Market Cap
$375.76M
PE Ratio
N/A
TTM Avg
4952.81
3Y Avg
4952.81
5Y Avg
4952.81
Market Cap
$374.62M
PE Ratio
N/A
TTM Avg
20.42
3Y Avg
20.42
5Y Avg
20.42
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| YD Bio Limited Ordinary Shares (YDES) | $379.85M | N/A | N/A | N/A | N/A |
| Orthofix Medical Inc. (OFIX)vs › | $382.19M | N/A | 157.27 | 122.07 | 183.95 |
| Zura Bio Limited (ZURA)vs › | $382.51M | N/A | N/A | N/A | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.19M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $375.76M | N/A | 4952.81 | 4952.81 | 4952.81 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $374.62M | N/A | 20.42 | 20.42 | 20.42 |
| REGENXBIO Inc. (RGNX)vs › | $388.35M | N/A | 13.34 | 13.34 | 21.63 |
| Opus Genetics, Inc. (IRD)vs › | $362.05M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $399.42M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $402.54M | N/A | 22.42 | 51.74 | 51.74 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
